THE #1 PRESCRIBED TREATMENT1
HYPOACTIVE SEXUAL DESIRE DISORDER IN PREMENOPAUSAL WOMEN
Addyi is indicated for the treatment of premenopausal women with acquired, generalized Hypoactive Sexual Desire Disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance.
Acquired HSDD refers to HSDD that develops in a patient who previously had no problems with sexual desire. Generalized HSDD refers to HSDD that occurs regardless of the type of stimulation, situation or partner. Addyi is not indicated for the treatment of HSDD in postmenopausal women, men or to enhance sexual performance.
THE ONLY FDA-APPROVED PILL PROVEN SAFE AND EFFECTIVE AT TREATING HSDD
IN CERTAIN PREMENOPAUSAL WOMEN2
The most common adverse events were dizziness, somnolence, nausea, fatigue, insomnia and dry mouth.
In clinical trials Addyi demonstrated
STATISTICALLY SIGNIFICANT RESULTS
in some women.2
The efficacy of Addyi was established in three 24-week, randomized, double-blind, placebo-controlled trials of premenopausal women with acquired, generalized HSDD. Patients in these trials were treated with Addyi 100mg (n=1187) once-daily at bedtime, or placebo (n=1188). Not all women will experience similar improvement in their HSDD.
INCREASED
SEXUAL Desire
INCREASED
Satisfying Sexual Events
REDUCED
Distress Associated With Low Sexual Desire
*Satisfying sexual events were measured by number of times in a month and defined as satisfying sexual intercourse, oral sex, masturbation or genital stimulation by a partner.
Contact Us
844-PINK-PILL (844-746-5745)
info@sproutpharma.com
844-746-5745 x 3
medicalaffairs@sproutpharma.com